Shots:
The CHMP’s positive opinion of Iqirvo (PPAR agonist) + ursodeoxycholic acid (UDCA) for PBC adults having inadequate UDCA response or Iqirvo alone for UDCA intolerant patients was based on P-III (ELATIVE) study. EC’s decision is anticipated in Q3’24. The company has submitted Iqirvo for PBC to the MHRA
- The P-III (ELATIVE) study assessed Iqirvo (80mg, QD) vs PBO to treat PBC patients (n=161) having inadequate response or intolerance to UDCA
- Study reached the composite 1EP of BCR, showing 47% treatment benefit in 51% vs 4% of them at wk.52 with an ALP reduction of 41% in 15% vs 0% of them at wk.4 that was sustained till wk.52
Ref: Ipsen | Image: Ipsen| Press Release
Related News:- LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
